Supporting innovative medical technology is key to Team Europe’s response to the Coronavirus pandemic: this is why the European Investment Bank, together with the European Commission, is backing German biopharmaceutical company BioNTech’s COVID-19 vaccine development and manufacturing programme with up to €100 million in debt financing under the Investment Plan for Europe.
Find out more on our support to BioNTech’s COVID-19 vaccine development programme
